Journal of Genetic Medicine

Korean Society of Medical Genetics and Genomics (대한의학유전학회)
권호 표지
DOI QR코드

DOI QR Code

Prenatal Population Screening for Fragile X Carrier and the Prevalence of Premutation Carriers in, Korea

  • Han, Sung-Hee (Division of Molecular Genetics, Department of Laboratory Medicine, Seoul Medical Science Institute, Seoul Clinical Laboratories) ;
  • Heo, Yun-Ah (Division of Molecular Genetics, Department of Laboratory Medicine, Seoul Medical Science Institute, Seoul Clinical Laboratories) ;
  • Yang, Young-Ho (Division of Molecular Genetics, Department of Laboratory Medicine, Seoul Medical Science Institute, Seoul Clinical Laboratories) ;
  • Kim, Young-Jin (Division of Molecular Genetics, Department of Laboratory Medicine, Seoul Medical Science Institute, Seoul Clinical Laboratories) ;
  • Cho, Han-Ik (Division of Molecular Genetics, Department of Laboratory Medicine, Seoul Medical Science Institute, Seoul Clinical Laboratories) ;
  • Lee, Kyoung-Ryul (Division of Molecular Genetics, Department of Laboratory Medicine, Seoul Medical Science Institute, Seoul Clinical Laboratories)
  • Received : 2012.11.08
  • Accepted : 2012.12.22
  • Published : 2012.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Fragile X carrier detection before or at early pregnancy through a wide screening program may not only confer a risk of having offspring with Fragile X syndrome (FXS), but may also confer a risk for Fragile X-associated primary ovarian insufficiency and Fragile X-associated tremor/ataxia syndrome. However, prior to the implementation of such a program, the carrier prevalence in a population and the availability of effective screening test should be evaluated. The aim of our study was to determine the prevalence of premutation carriers and to evaluate the feasibility of screening test. Materials and Methods: The blood samples were obtained from 8,641 pregnant women with no family history of mental retardation. We performed a three-primer CGG repeat primed (RP) PCR using the AmplideX$^{TM}$ FMR1 PCR kit (Asuragen, Inc. Austin, TX, USA). Samples showing full mutation alleles were reflexed to Southern blot analysis for methylation status and sizing. Results: Among the 8,641 women, we found 8 premutation carriers (1:1,090, 0.09%) and 46 women with an intermediate allele (1:190, 0.53%). No woman was found to carry the fully mutated allele. All the detected alleles were within the CGG repeat range of 8-117. Among the 8,641 samples, 29 and 30 CGG repeats represent 66.6% of all cases. The CGG RP PCR method provides robust detection of expanded alleles and resolves allele zygosity, thus minimizing the number of samples that require Southern blot analysis. Conclusion: This is the first study that has focused on the prevalence of FXS premutation carriers and FMR1 allele distribution in normal pregnant women. These data have important implications for population-based fragile X carrier screening in Korea.

Keywords

References

  1. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, et al. Warren Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991;65:905-14. https://doi.org/10.1016/0092-8674(91)90397-H
  2. Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol 2007;6:45-55. https://doi.org/10.1016/S1474-4422(06)70676-7
  3. Musci TJ, Moyer K. Prenatal carrier testing for fragile X: counseling issues and challenges. Obstet Gynecol Clin North Am 2010;37:61-70. https://doi.org/10.1016/j.ogc.2010.03.004
  4. Filipovic-Sadic S, Sah S, Chen L, Krosting J, Sekinger E, Zhang W, et al. A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. Clin Chem 2010;56:399-408.
  5. Tassone F, Pan R, Amiri K, Taylor AK, Hagerman PJ. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn 2008;10:43-9. https://doi.org/10.2353/jmoldx.2008.070073
  6. Maddalena A, Richards CS, McGinniss MJ, Brothman A, Desnick RJ, Grier RE, et al. Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. Quality Assurance Subcommittee of the Laboratory Practice Committee. Genet Med 2001;3:200-5. https://doi.org/10.1097/00125817-200105000-00010
  7. Pesso R, Berkenstadt M, Cuckle H, Gak E, Peleg L, Frydman M, et al. Screening for fragile X syndrome in women of reproductive age. Prenat Diagn 2000;20:611-4. https://doi.org/10.1002/1097-0223(200008)20:8<611::AID-PD881>3.0.CO;2-M
  8. Toledano-Alhadef H, Basel-Vanagaite L, Magal N, Davidov B, Ehrlich S, Drasinover V, et al. Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am J Hum Genet 2001;69:351-60. https://doi.org/10.1086/321974
  9. Berkenstadt M, Ries-Levavi L, Cuckle H, Peleg L, Barkai G. Preconceptional and prenatal screening for fragile X syndrome: experience with 40,000 tests. Prenat Diagn 2007;27:991-4. https://doi.org/10.1002/pd.1815
  10. Spence WC, Black SH, Fallon L, Maddalena A, Cummings E, Menapace- Drew G, et al. Molecular fragile X screening in normal populations. Am J Med Genet 1996;64:181-3. https://doi.org/10.1002/(SICI)1096-8628(19960712)64:1<181::AID-AJMG31>3.0.CO;2-H
  11. Cronister A, DiMaio M, Mahoney MJ, Donnenfeld AE, Hallam S. Fragile Xsyndrome carrier screening in the prenatal genetic counseling setting. Genet Med 2005;7:246-50. https://doi.org/10.1097/01.GIM.0000159898.90221.D3
  12. Ryynänen M, Heinonen S, Makkonen M, Kajanoja E, Mannermaa A, Pertti K. Feasibility and acceptance of screening for fragile X mutations in low-risk pregnancies. Eur J Hum Genet 1999;7:212-6. https://doi.org/10.1038/sj.ejhg.5200285
  13. Kallinen J, Marin K, Heinonen S, Mannermaa A, Palotie A & Ryynänen M Wide scope prenatal diagnosis at Kuopio University Hospital 1997- 1998: integration of gene tests and fetal karyotyping. Br J Obstet Gynaecol 2001;108: 505-9.
  14. Hill MK, Archibald AD, Cohen J, Metcalfe SA. A systematic review of population screening for fragile X syndrome. Genet Med 2010;12:396-410. https://doi.org/10.1097/GIM.0b013e3181e38fb6
  15. Otsuka S, Sakamoto Y, Siomi H, Itakura M, Yamamoto K, Matumoto H, et al. Fragile X carrier screening and FMR1 allele distribution in the Japanese population. Brain Dev 2010;32:110-4. https://doi.org/10.1016/j.braindev.2008.12.015
  16. Huang KF, Chen WY, Tsai YC, Lin CC, Chen SH, Tseng CY, et al. Original article pilot screening for fragile X carrier in pregnant women of southern. Taiwan J Chin Med Assoc 2003;66:204-9.
  17. Song KH, Kim GJ, Whang YJ, Choi SR, Lee SP, Whang BC, et al. Allele distribution of FMR1 gene in Korean women. Kor J Obstet Gynecol 2002;45:990-3.
  18. Hill MK, Archibald AD, Cohen J, Metcalfe SA. A systematic review of population screening for fragile X syndrome. Genet Med 2010;12:396-410. https://doi.org/10.1097/GIM.0b013e3181e38fb6
  19. Peprah E. Fragile X syndrome: the FMR1 CGG repeat distribution among world populations. Ann Hum Genet 2012;76:178-91. https://doi.org/10.1111/j.1469-1809.2011.00694.x
  20. Haddad LA, Mingroni-Netto RC, Vianna-Morgante AM, Pena SD. A PCR-based test suitable for screening for fragile X syndrome among mentally retarded males. Hum Genet 1996;97:808-12. https://doi.org/10.1007/BF02346194
  21. Brown WT, Nolin S, Houck G Jr, Ding X, Glicksman A, Li SY, et al. Prenatal diagnosis and carrier screening for fragile X by PCR. Am J Med Genet 1996;64:191-5. https://doi.org/10.1002/(SICI)1096-8628(19960712)64:1<191::AID-AJMG34>3.0.CO;2-G
  22. Chen L, Hadd A, Sah S, Filipovic-Sadic S, Krosting J, Sekinger E, et al. An information-rich CGG repeat primed PCR that detects the full range of fragile X expanded alleles and minimizes the need for southern blot analysis. J Mol Diagn 2010;12:589-600. https://doi.org/10.2353/jmoldx.2010.090227